Science - USA (2022-01-14)

Fasslet al.,Science 375 , eabc1495 (2022) 14 January 2022 12 of 19

Table 4. Ongoing clinical trials testing new combinations with CDK4/6 inhibitors.HR+, hormone receptor–positive; LHRH, luteinizing hormone–releasing

hormone; ER+, estrogen receptor–positive; PD-1, programmed cell death protein 1; PD-L1, programmed cell death 1 ligand 1; AR+, androgen receptor–positive;

TNBC, triple-negative breast cancer; EGFR, epidermal growth factor receptor; HER2+, human epidermal growth factor receptor 2–positive; FGFR, fibroblast

growth factor receptor; IGFR, insulin-like growth factor receptor; VEGF, vascular endothelial growth factor receptor; PI3K, phosphoinositide 3-kinase; NSCLC,

non–small-cell lung cancer; ALL, acute lymphoblastic leukemia; SCLC, small-cell lung cancer.

Additional target Inhibitor Immune

checkpoint

inhibitor

Tumor

type

Trial identifier

Palbociclib

............................................................................................................................................................................................................................................................................................................................................

Aromatase Letrozole, anastrozole,

exemestane

HR+breast cancer, HR+ovarian

cancer, metastatic breast cancer,

metastatic endometrial cancer

NCT04130152, NCT03054363,

NCT03936270, NCT04047758,

NCT02692755, NCT02806050,

NCT03870919, NCT02040857,

NCT04176354, NCT02028507,

NCT03220178, NCT02592083,

NCT02603679, NCT04256941,

NCT03425838, NCT02894398,

NCT02297438, NCT02730429,

............................................................................................................................................................................................................................................................................................................................................NCT02142868, NCT02942355

LHRH LHRH agonists: goserelin,

leuprolide

HR+breast cancer NCT03969121, NCT03423199,

NCT01723774, NCT02917005,

............................................................................................................................................................................................................................................................................................................................................NCT02592746, NCT03628066

ER ER antagonists: fulvestrant,

tamoxifen

HR+breast cancer, metastatic

breast cancer

NCT02668666, NCT02738866,

NCT03184090, NCT04526028,

NCT02513394, NCT03560856,

NCT02760030, NCT03079011,

NCT03227328, NCT03809988,

NCT02764541, NCT03007979,

............................................................................................................................................................................................................................................................................................................................................NCT03633331

ER Selective estrogen receptor

degraders (SERDs): G1T48,

ZN-c5, SAR439859,

AZD9833, GDC-9545

HR+breast cancer NCT03455270, NCT04546009,

NCT04436744, NCT04478266,

NCT03560531, NCT03616587,

............................................................................................................................................................................................................................................................................................................................................NCT03284957, NCT03332797

ER Selective estrogen receptor

modulator (SERM):

bazedoxifene

HR+breast cancer NCT03820830, NCT02448771

............................................................................................................................................................................................................................................................................................................................................

Aromatase + PD-1 Letrozole, anastrozole Pembrolizumab,

nivolumab

Stage IV ER+

breast cancer

NCT02778685, NCT04075604

............................................................................................................................................................................................................................................................................................................................................

PD-1 Nivolumab,

pembrolizumab,

MGA012

Liposarcoma NCT04438824

............................................................................................................................................................................................................................................................................................................................................

PD-L1 Avelumab AR+breast cancer, TNBC,

ER+/HER2–metastatic

breast cancer

NCT04360941, NCT03147287

............................................................................................................................................................................................................................................................................................................................................

EGFR + PD-L1 Cetuximab Avelumab Squamous cell carcinoma

of the head and neck

NCT03498378

............................................................................................................................................................................................................................................................................................................................................

HER2 Tucatinib, trastuzumab,

pertuzumab,

T-DM1, ZW25

HER2+breast cancer NCT03530696, NCT03054363,

NCT02448420, NCT03709082,

............................................................................................................................................................................................................................................................................................................................................NCT03304080, NCT02947685

EGFR/HER2 Neratinib Advanced solid tumors with

EGFR mutation/amplification,

HER2 mutation/amplification,

HER3/4 mutation, or

KRAS mutation

NCT03065387

............................................................................................................................................................................................................................................................................................................................................

EGFR Cetuximab Metastatic colorectal cancer,

squamous cell carcinoma

of the head and neck

NCT03446157, NCT02499120

............................................................................................................................................................................................................................................................................................................................................

FGFR Erdafitinib ER+/HER2–/FGFR-amplified

metastatic breast cancer

NCT03238196

continued on next page............................................................................................................................................................................................................................................................................................................................................

RESEARCH | REVIEW